Truist Securities Downgrades Corcept Therapeutics (CORT) to Hold
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $122.25 +0.99%
Rating Summary:
8 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Truist Securities analyst Gregory Fraser downgraded Corcept Therapeutics (NASDAQ: CORT) from Buy to Hold with a price target of $30.00.
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $28.66 yesterday.
You May Also Be Interested In
- Truist Securities Assumes Corcept Therapeutics (CORT) at Buy
- Goldman Sachs Downgrades Kuaishou Technology (1024:HK) to Neutral
- Baird Downgrades Teradyne (TER) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
